SAHA Regulates Histone Acetylation, Butyrylation, and Protein Expression in Neuroblastoma
文献类型：期刊论文
| 作者 | Xu, Guofeng1; Wang, Jun1; Wu, Zhixiang2,3; Qian, Lili2,3; Dai, Lunzhi4; Wan, Xuelian2,3; Tan, Minjia2,3 ; Zhao, Yingming4; Wu, Yeming1
|
| 刊名 | JOURNAL OF PROTEOME RESEARCH
 |
| 出版日期 | 2014-10 |
| 卷号 | 13期号:10页码:4211-4219 |
| 关键词 | histone deacetylase (HDAC) suberoylanilide hydroxamic acid (SAHA) lysine acetylation lysine butyrylation neuroblastoma quantitative proteomics |
| ISSN号 | 1535-3893 |
| DOI | 10.1021/pr500497e |
| 文献子类 | Article |
| 英文摘要 | Emerging evidence suggests that suberoylanilide hydroxamie acid (SAHA), a clinically approved HDAC inhibitor for cutaneous T-cell lymphoma, shows promising clinical benefits in neuroblastoma, the most common extra cranial solid neoplasm with limited choice of therapeutic intervention. However, the molecular mechanism under which the compound exerts its antitumor effect remains elusive. Here we report a quantitative proteomics study that determines changes of protein expression, histone lysine acetylation, and butyrylation in response to SAHA treatment. We detected and quantified 28 histone lysine acetylation and 18 histone lysine butyrylation marks most of which are dramatically induced by SAHA. Importantly, we identified 11 histone K-bu sites as novel histone marks in human cells. Furthermore, quantitative proteomic analysis identified 5426 proteins, amond which 510 proteins were up-regulated and 508 proteins were down-regulated (significant p value <0.05). The subsequent bioinformatics analysis identified distinct SAHA-response gene ontology (GO) categories and signaling pathways, including cellular metabolism and DNA-dependent pathways. Our study therefore reveals new histone epigenetic marks and offers key insights into the molecular mechanism by which SAHA regulates proteomic changes in neuroblastoma cells and identifies biomarker candidates for SAHA. |
| WOS关键词 | DEACETYLASE INHIBITORS ; LYSINE PROPIONYLATION ; CELLS ; IDENTIFICATION ; VORINOSTAT ; DIFFERENTIATION ; QUANTIFICATION ; CONSORTIUM ; ACETYLOME ; TRIAL |
| 资助项目 | National Natural Science Foundation of China[81272803] |
| WOS研究方向 | Biochemistry & Molecular Biology |
| 语种 | 英语 |
| WOS记录号 | WOS:000342719200001 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276885]  |
| 专题 | 化学蛋白质组学研究中心 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Zhao, Yingming |
| 作者单位 | 1.Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Surg, Shanghai 200092, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Chem Prote Ctr, Shanghai 201203, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 4.Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA |
| 推荐引用方式 GB/T 7714 | Xu, Guofeng,Wang, Jun,Wu, Zhixiang,et al. SAHA Regulates Histone Acetylation, Butyrylation, and Protein Expression in Neuroblastoma[J]. JOURNAL OF PROTEOME RESEARCH,2014,13(10):4211-4219. |
| APA | Xu, Guofeng.,Wang, Jun.,Wu, Zhixiang.,Qian, Lili.,Dai, Lunzhi.,...&Wu, Yeming.(2014).SAHA Regulates Histone Acetylation, Butyrylation, and Protein Expression in Neuroblastoma.JOURNAL OF PROTEOME RESEARCH,13(10),4211-4219. |
| MLA | Xu, Guofeng,et al."SAHA Regulates Histone Acetylation, Butyrylation, and Protein Expression in Neuroblastoma".JOURNAL OF PROTEOME RESEARCH 13.10(2014):4211-4219. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。